Ciclesonide is a new inhaled glucocorticoid drug for treating asthma,it belongs to adrenocorticotropic hormone drugs, similar drugs also include beclomethasone dipropionate, budesonide, fluticasone propionate, the product is administrated in a non-active form ,it can be activated by endogenous esterases in the airway on the spot , it becomes into an active ingredient when it reaches the target organ-the lung; once it is activated, it shows a high topical anti-inflammatory activity.
Ciclesonide is successfully developed by the pharmaceutical company Altana, it was listed in January 2005 for the first time in the UK, it is currently available in Germany, Ireland, it is used for the treatment of adults with all levels of persistent severe asthma, one administration per day , a dose of 160μg or 80μg. For patients with severe asthma attack facing the risk of asthma, if the condition can not be controlled and strong anti-inflammatory drugs are required , the dose of this product be increased to 160μg.
In clinical trail phase III of severe patients with persistent asthma, ciclesonide has new release and distribution properties,it can reduce the local and systemic adverse reactions, and it can maintain high anti-asthma activity, it can significantly low the need on oral corticosteroids (OCS) in patients to maintain or improve effects of asthma control. Accordingly, it is an appropriate OCS saving therapy.
Ciclesonide becomes effective faster than budesonide,its systemic side effects are lower than the fluticasone propionate and budesonide, even though the highest doses of 160μg is used, plasma glucocorticoid inhibition is also higher than other corticosteroids inhalants (if high plasma corticosterone hormone levels are high ,the systemic side effects is high).
Local side effects comparison table is as follows:
Side effects of this product fluticasone propionate budesonide
Dysphonia (hoarseness) 1.6% 4% 1%-8%-6%
Sore throat 1.9% 10%-14% 5%-10%
Thrush 0.2%-5% 2% 2%-4%
The above information is edited by the chemicalbook of Tian Ye.
